Adaptive Biotechnologies (ADPT) Raised MRD Guidance, Is The Stock Fairly Valued?
Q2 earnings report and raised MRD guidance put Adaptive Biotechnologies in focus
Adaptive Biotechnologies (ADPT) drew fresh investor attention after reporting second quarter 2026 results and updating its full year outlook for the Minimal Residual Disease, or MRD, business.
The company reported quarterly sales of US$71.55 million and a net loss of US$39.79 million. It also raised expected 2026 MRD revenue to a range of US$268 million to US$278 million.
See our latest analysis for Adaptive Biotechnologies.
Adaptive Biotechnologies shares have been volatile around the Q2 earnings release, with a 1 day share price return of down 6.66%. However, the 90 day share price return of 58.16% and 1 year total shareholder return of 118.49% point to strong momentum over the past year, even as the 5 year total shareholder return remains down 36.08%.
If Adaptive Biotechnologies has you rethinking where growth in healthcare could come from next, it may be worth sizing up 41 healthcare AI stocks
After a sharp one year rebound, investors now face a harder question on Adaptive Biotechnologies. Do current expectations around MRD guidance and ongoing losses still leave enough upside to justify the risk at today’s price?
Most Popular Narrative: 1% Overvalued
Analysts in the most followed narrative place Adaptive Biotechnologies' fair value at $22.29, slightly below the last close at $22.57, which frames a very tight valuation band.
Marked improvement in profitability, with the MRD segment now EBITDA positive and company-wide cash burn improving 36% year-over-year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise.
Want to see what sits behind that fair value call? The narrative leans on ambitious revenue compounding, margin lift and a rich future earnings multiple. Curious which assumptions matter most.
Result: Fair Value of $22.29 (ABOUT RIGHT)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear pressure points for Adaptive Biotechnologies, including ongoing company-level losses and heavy reliance on a small group of key partners.
Find out about the key risks to this Adaptive Biotechnologies narrative.
Another view on Adaptive Biotechnologies’ valuation
Analysts using a SWS DCF model see Adaptive Biotechnologies as trading about 5.4% below an estimated fair value of US$23.86. That sits slightly above the US$22.29 narrative fair value and the current US$22.57 price. This raises the question of whether the stock is a mild opportunity or simply fairly priced with additional risk attached.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Adaptive Biotechnologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If the mix of optimism and caution around Adaptive Biotechnologies feels finely balanced, it may be useful to review the data and test the numbers yourself. To see what investors are focusing on, start by weighing the company's 3 key rewards
Looking for more investment ideas beyond Adaptive Biotechnologies?
Do not stop with Adaptive Biotechnologies. Apply the same discipline across your portfolio and you may improve your chances of identifying the next standout opportunity.
- Target companies that combine quality and a potential valuation gap by scanning the 55 high quality undervalued stocks.
- Strengthen your income stream by reviewing the 9 dividend fortresses to see which payouts currently stand out.
- Cut portfolio stress by focusing on resilience first and checking the 81 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com